46 results
S-3
EX-1.2
MREO
Mereo Biopharma Group Plc
15 May 24
Shelf registration
4:49pm
and has no knowledge that the FDA or any Governmental Entity or third party is considering any such claim, litigation, arbitration, action, suit … , without re-examination or review of the merits of the cause of action in respect of which the original judgment was given or re-litigation of the matters
S-3
MREO
Mereo Biopharma Group Plc
15 May 24
Shelf registration
4:49pm
such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal
10-Q
2024 Q1
MREO
Mereo Biopharma Group Plc
15 May 24
Quarterly report
4:19pm
such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal … commitments with CMOs of $3.1 million as of March 31, 2024.
Legal proceedings
From time to time, the Company may be a party to litigation or subject
10-K
2023 FY
EX-10.30
MREO
Mereo Biopharma Group Plc
27 Mar 24
Annual report
5:20pm
, experience, techniques, data and the results of experimentation and testing;
“Litigation Conditions” has the meaning set forth in Section 8.4 … of any of the following: (a) any pending or threatened litigation, governmental investigation, proceeding or action involving the Product; (b) any
10-K
2023 FY
MREO
Mereo Biopharma Group Plc
27 Mar 24
Annual report
5:20pm
statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All … liabilities in respect of such sales or out-licensing arrangements. We may be required to pay damages (including, but not limited to, litigation
10-K
EX-19.1
r72hjjr2q
27 Mar 24
Annual report
5:20pm
6-K
EX-99.1
da3noxd
17 Oct 23
Current report (foreign)
7:01am
6-K
EX-99.1
0fj8a
6 Jul 23
Ultragenyx Announces First Patients Dosed in Phase 3 Program
8:05am
6-K
EX-99.1
7a25v
5 Jun 23
Ultragenyx and Mereo BioPharma Announce Positive Data from the Ongoing Phase 2/3 Orbit
4:37pm
6-K
EX-99.2
78t56gkecg8ywcnspo4c
28 Oct 22
Mereo BioPharma Reaches Cooperation Agreement with Rubric Capital Management
7:11am
6-K
EX-99.1
9fjroen0kap23p
1 Oct 21
Current report (foreign)
4:43pm
F-3
EX-1.2
40q6eph
5 Aug 21
Shelf registration (foreign)
4:33pm
6-K
EX-1.1
mlc8j6736w as
10 Feb 21
Mereo BioPharma Group plc Announces Proposed Public Offering of American Depositary Shares
5:23pm
424B5
jv1memw u8
10 Feb 21
Prospectus supplement for primary offering
4:53pm
424B5
nshyxlxrththr7i9 kf0
9 Feb 21
Prospectus supplement for primary offering
5:24pm
6-K
EX-99.1
kaq3ttf
17 Dec 20
Mereo BioPharma and Ultragenyx Announce Collaboration and License
5:16pm